Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.59 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28881815 | 0.84 | BTK (0.70) | PTPN11BTKCKS1BSKP1SKP2 | |
| SCHEMBL16671225 | 0.83 | BTK (0.71) | BTKSLC6A7 | |
| SCHEMBL30422880 | 0.82 | PTPN11 (0.55) | PTPN11ACHECKS1BSKP1SKP2 | |
| SCHEMBL31148409 | 0.82 | PTPN11 (0.55) | PTPN11ACHECKS1BSKP1SKP2 | |
| SCHEMBL16676723 | 0.81 | BTK (0.48) | BTKSLC6A7 | |
| SCHEMBL16671473 | 0.80 | BTK (0.67) | BTK | |
| Hydrochloric Acid SCHEMBL16670652 | 0.80 | BTK (0.48) | BTKSLC6A7 | |
| SCHEMBL16670692 | 0.80 | HPGDS (0.46) | BTKPARP1 | |
| SCHEMBL16671267 | 0.79 | TNK2 (0.46) | PTPN11BTK | |
| SCHEMBL16670316 | 0.78 | BTK (0.49) | BTKPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | PTPN11 74/4885BTK 1/4885ACHE 3957/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | PTPN11 74/4885BTK 1/4885ACHE 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.